Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review - Hong, Dongzhe; Si, Lei; Jiang, Minghuan; Shao, Hui; Ming, Wai-kit; Zhao, Yingnan; Li, Yan; Shi, Lizheng (PharmacoEconomics, 2019)
Keywords: Antidiabetics; Cost analysis; Cost-Benefit Analysis; Developing countries; Diabetes; Dipeptidyl-Peptidase IV Inhibitors - economics; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Disease; Economics; GLP-1 receptor agonists; Glucagon; Glucagon-Like Peptide-1 Receptor - agonists; Glucose; Health Administration; Health care expenditures; Health Economics; Health technology assessment; Humans; Hypoglycemia; Hypoglycemic Agents - economics; Hypoglycemic Agents - therapeutic use; Insulin - therapeutic use; Insulin resistance; LDCs; Libraries; Medicine; Medicine & Public Health; Peptides; Pharmacoeconomics and Health Outcomes; Public Health; Quality; Quality of Life Research; Reimbursement; Sensitivity analysis; Sodium; Sodium-Glucose Transporter 2 Inhibitors - economics; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Systematic Review